Research programme: ion channel modulators - ArQuleAlternative Names: Ion channel modulators research programme - ArQule
Latest Information Update: 19 Jun 2006
At a glance
- Originator ArQule
- Mechanism of Action Calcium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 12 Feb 2004 Ion channel modulator is available for licensing (http://www.arqule.com)
- 13 Aug 2003 Preclinical trials in Neuropathic pain in USA (unspecified route)